logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

AACR 2019—Ipilimumab-nivolumab yields 42% response rate in high-grade neuroendocrine cancer

A potential alternative to aggressive, toxic chemotherapy.